Tokyo Tape
Sign in
← Vital Ksk Holdings

Half-year report · Q2

3151.TEDINET S100UNVO
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥297.1bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥587.5bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥294.2bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥2.9bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥2.9bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥3.6bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥6.6bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.5bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥3.7bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥3.5bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥2.4bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥5.8bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.3bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.5bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥2.4bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥317.6bnat 2024-09-30Cons.Assets
Total assets¥317.3bnat 2024-03-31Cons.Assets
Total assets¥321.7bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥207.9bnat 2024-09-30Cons.Liabilities
Total liabilities¥211.3bnat 2024-03-31Cons.Liabilities
Net assets / equity¥109.6bnat 2024-09-30Cons.Net assets
Net assets / equity¥105.9bnat 2024-03-31Cons.Net assets
Net assets / equity¥102.8bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥19.7bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥34.7bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥16.1bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥31.1bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥26.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥15.1bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow−¥9.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥23.6bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥16.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥3.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥48.752024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥115.032023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥45.782023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio34.1%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.0%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2024-09-30¥3.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2024-09-30¥2.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-04-01 → 2024-09-30¥1.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2024-09-30−¥88m
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥6.8bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥6.8bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30¥0
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue2024-04-01 → 2024-09-30¥285.0bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue external2024-04-01 → 2024-09-30¥279.5bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentsegment profit2024-04-01 → 2024-09-30¥2.7bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥9.7bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥9.7bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥6m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥96m
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥5.6bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥5.6bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥0
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥144m
—segment totalrevenue2024-04-01 → 2024-09-30¥300.4bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥294.9bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥5.5bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥3.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥303.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥297.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥6.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥2.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥3.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥1.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30−¥108m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥6.6bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥6.6bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30¥39m
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue2023-04-01 → 2023-09-30¥282.5bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue external2023-04-01 → 2023-09-30¥277.2bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥5.3bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentsegment profit2023-04-01 → 2023-09-30¥2.6bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥9.4bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥9.4bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥6m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥114m
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.6bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.6bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥0
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥183m
—segment totalrevenue2023-04-01 → 2023-09-30¥297.5bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥292.2bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥5.3bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥2.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥300.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥294.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥6.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥2.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 543
ItemContextValueUnit
Noncurrent liabilitiesPrior1YearInstant17910000000JPY
Noncurrent liabilitiesCurrentQuarterInstant18558000000JPY
LiabilitiesPrior1YearInstant211317000000JPY
LiabilitiesCurrentQuarterInstant207942000000JPY
Capital stockPrior1YearInstant5000000000JPY
Capital stockCurrentQuarterInstant5000000000JPY
Capital surplusPrior1YearInstant5272000000JPY
Capital surplusCurrentQuarterInstant5272000000JPY
Retained earningsPrior1YearInstant71339000000JPY
Retained earningsCurrentQuarterInstant72603000000JPY
Treasury stockPrior1YearInstant-1653000000JPY
Treasury stockCurrentQuarterInstant-3193000000JPY
Shareholders equityPrior1YearInstant79958000000JPY
Shareholders equityCurrentQuarterInstant79682000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant22749000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant26857000000JPY
Remeasurements of defined benefit plansPrior1YearInstant1956000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant1745000000JPY
Valuation and translation adjustmentsPrior1YearInstant24705000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant28602000000JPY
Non controlling interestsPrior1YearInstant1276000000JPY
Non controlling interestsCurrentQuarterInstant1341000000JPY
Net assetsPrior1YearInstant105940000000JPY
Net assetsCurrentQuarterInstant109626000000JPY
Liabilities and net assetsPrior1YearInstant317258000000JPY
Liabilities and net assetsCurrentQuarterInstant317568000000JPY
Net salesPrior1YTDDuration294213000000JPY
Net salesCurrentYTDDuration297079000000JPY
Cost of salesPrior1YTDDuration270626000000JPY
Cost of salesCurrentYTDDuration273264000000JPY
Gross profitPrior1YTDDuration23587000000JPY
Gross profitCurrentYTDDuration23814000000JPY
Selling general and administrative expensesPrior1YTDDuration20719000000JPY
Selling general and administrative expensesCurrentYTDDuration20938000000JPY
Operating incomePrior1YTDDuration2868000000JPY
Operating incomeCurrentYTDDuration2876000000JPY
Interest income noiPrior1YTDDuration33000000JPY
Interest income noiCurrentYTDDuration23000000JPY
Dividends income noiPrior1YTDDuration326000000JPY
Dividends income noiCurrentYTDDuration361000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration28000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration42000000JPY
Rent income noiPrior1YTDDuration130000000JPY
Rent income noiCurrentYTDDuration130000000JPY
Gain on redemption of securities noiPrior1YTDDuration－JPY
Gain on redemption of securities noiCurrentYTDDuration239000000JPY
Other noiPrior1YTDDuration199000000JPY
Other noiCurrentYTDDuration69000000JPY
Non operating incomePrior1YTDDuration717000000JPY
Non operating incomeCurrentYTDDuration867000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass